On the good side, as low STAT5 signaling parallels luminal differentiation, pharmacological STAT5 inhibitors are not expected to result in tumor enrichment in stem/progenitor cells, but they can also act on the stromal cells such as immune cells. Here, STAT5B is linked to neoplasm.